CN1732949A - Composition of cefuroxime sodium and tazobactam sodium for injection - Google Patents
Composition of cefuroxime sodium and tazobactam sodium for injection Download PDFInfo
- Publication number
- CN1732949A CN1732949A CN 200510090387 CN200510090387A CN1732949A CN 1732949 A CN1732949 A CN 1732949A CN 200510090387 CN200510090387 CN 200510090387 CN 200510090387 A CN200510090387 A CN 200510090387A CN 1732949 A CN1732949 A CN 1732949A
- Authority
- CN
- China
- Prior art keywords
- sodium
- tazobactam
- cefuroxime
- injection
- staphylococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses cefuroxime sodium and tazobactam sodium compositions for injection, which comprises cefuroxime sodium and tazobactam sodium by the weight ratio of 15:1. These compositions have better antibiotic action.
Description
Technical field
The present invention relates to a kind of antibacterial combination, is a kind of anti-beta-lactamase antibiotic composite preparation.
Background technology
(Cefuroxime CXM) is second generation cephalosporin to cefuroxime, as a kind of broad-spectrum sterilization antibiotic, gram positive bacteria and most gram negative bacteria is all had stronger antibacterial action, and liver, nephrotoxicity are low.Along with cefuroxime extensive use clinically, the original responsive bacterial strain of part has produced drug resistance to cefuroxime, and its antibacterial effect is descended.Discover that antibacterial produces chemical sproof main mechanism to cephalosporins medicine and decomposes medicine for producing specific beta-lactamase.
Produce the drug resistance that the beta-lactamase antibacterial is caused for overcoming, people begin to develop the anti-beta-lactamase antibiotic composite preparation of cefuroxime and Tazobactam Sodium composition, and obtained certain achievement, test shows that this compound preparation obviously is better than cefuroxime to in-vitro antibacterial and the bactericidal activity of staphylococcus aureus, colon bacillus, Klebsiella pneumonia, Pseudomonas aeruginosa, acinetobacter calcoaceticus, generation bacillus, shigella flexneri and the enterobacter cloacae of product enzyme.For example among the disclosed Chinese patent literature CN1513457A on July 21st, 2004, a kind of anti-beta-lactamase antibiotic composite preparation of being made up of cefuroxime and salt thereof and Tazobactam Sodium and salt thereof is disclosed.Think in this patent documentation that the preferred weight ratio scope of cefuroxime and salt thereof and Tazobactam Sodium and salt thereof is 1: 1 to 10: 1, best weight ratio is 2: 1, under this optimum weight ratio condition, this compound preparation is to the MIC of staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, colon bacillus, Klebsiella pneumonia, Pseudomonas aeruginosa, acinetobacter calcoaceticus, generation bacillus, shigella flexneri and the enterobacter cloacae of product enzyme
50Minimum with MIC90.
But,, caused in the prior art price of this compound preparation higher, not easy for patients to accept because the price of sodium-tazobactam is very high.
The inventor is by studying for a long period of time and a large amount of test, found new best proportioning, under this conditions of mixture ratios, the anti-beta-lactamase antibiotic composite preparation of Cefuroxime Sodium and sodium-tazobactam is that 2: 1 o'clock in-vitro antibacterial, bactericidal effect is suitable to the weight ratio of disclosed Cefuroxime Sodium and sodium-tazobactam among extracorporeal disinfecting, antibacterial effect and the CN1513457A of the antibacterial that produces enzyme, and cost is lower, and patient Geng Yi accepts.
Summary of the invention
The drug-fast problem that directed toward bacteria produces Cefuroxime Sodium, the objective of the invention is to provide the compound preparation that a kind of combination of Cefuroxime sodium and tazobactam for injection constitutes, the in-vitro antibacterial of this preparation, bactericidal effect are equal to the effect of present similar preparation, but cost is lower.
Cefuroxime sodium for injection provided by the invention and sodium-tazobactam compound preparation are made up of hot sodium of cephalo and sodium-tazobactam, and the weight ratio of described Cefuroxime Sodium and sodium-tazobactam is 15: 1.
This cefuroxime sodium for injection of the present invention and sodium-tazobactam compound preparation, its in-vitro antibacterial and sterilization and existing Cefuroxime Sodium and sodium-tazobactam weight ratio are that the compound preparation that constituted in 2: 1 o'clock is suitable, but to face upward the consumption of expensive Tazobactam Sodium lower for price in the compound preparation, thereby the unit administration cost is minimum, can alleviate patient's burden greatly.
The specific embodiment
Be described further below in conjunction with the compositions of specific embodiment hot sodium of this present invention's injection cephalo and sodium-tazobactam formation.
Embodiment 1
Combination of Cefuroxime sodium and tazobactam for injection is made up of Cefuroxime Sodium and sodium-tazobactam, and the weight ratio of Cefuroxime Sodium and sodium-tazobactam is 15: 1.
Comparative experimental example
Sample:
A: cefuroxime sodium for injection sodium-tazobactam (1: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.0g/ bottle
B: cefuroxime sodium for injection sodium-tazobactam (2: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.2g/ bottle
C: cefuroxime sodium for injection sodium-tazobactam (3: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.0g/ bottle
D: cefuroxime sodium for injection sodium-tazobactam (5: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.9g/ bottle
E: cefuroxime sodium for injection sodium-tazobactam (8: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.125g/ bottle
F: cefuroxime sodium for injection sodium-tazobactam (15: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.8g/ bottle
G: cefuroxime sodium for injection sodium-tazobactam (15: 2), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.85g/ bottle
H: cefuroxime sodium for injection, Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 2025g/ bottle
I: cefoperazone for inj sodium-tazobactam sodium (4: 1), Hainan GeneralSanyang Pharmaceutical Co., Ltd provides, specification: the 2.0g/ bottle
J: piperacillin sodium injection sodium-tazobactam (8: 1), Hainan GeneralSanyang Pharmaceutical Co., Ltd provides, specification: the 1.125g/ bottle
Test method: adopt the full dose broth dilution method determination
Test strain: clinical isolating staphylococcus aureus, escherichia coli, each two strain of Klebsiella Pneumoniae.
Result of the test sees Table 1 and table 2, and every kind of each row is all represented the result of the test to a strain bacterial strain.
Table 1: testing sample is to the MIC result (μ g/ml) of test strain
Test strain | A | B | C | D | E | F | G | H | I | J |
Staphylococcus aureus | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 8 | 0.25 | 4 |
1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
Escherichia coli | 4 | 4 | 2 | 2 | 4 | 4 | 8 | 128 | 0.5 | 4 |
2 | 2 | 1 | 2 | 2 | 4 | 4 | 128 | 2 | 1 | |
Klebsiella Pneumoniae | 2 | 0.5 | 0.25 | 0.25 | 0.5 | 1 | 1 | 4 | 0.25 | 0.25 |
4 | 2 | 2 | 2 | 4 | 4 | 8 | 256 | 1 | 4 |
Table 2:MIC outcome record is single
Code | Test strain | Medicament contg | No medicine contrast | ||||||||||||
256 | 128 | 64 | 32 | 16 | 8 | 4 | 2 | 1 | 0.5 | 0.25 | 0.125 | 0.0625 | |||
A | Staphylococcus aureus | - | - | - | - | - | - | - | - | + | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
B | Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | - | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
C | Staphylococcus aureus | - | - | - | - | - | - | - | - | - | - | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | - | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
D | Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
E | Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
F | Staphylococcus aureus | - | - | - | - | - | - | - | - | + | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
G | Staphylococcus aureus | - | - | - | - | - | - | - | - | + | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | + | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | + | + | + | + | + | + | + | + | |
H | Staphylococcus aureus | - | - | - | - | - | - | + | + | + | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | + | + | + | + | + | + |
Escherichia coli | - | - | + | + | + | + | + | + | + | + | + | + | + | + | |
Escherichia coli | - | - | + | + | + | + | + | + | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | + | + | + | + | + | + | + | + | + | + | + | + | + | |
I | Staphylococcus aureus | - | - | - | - | - | - | - | - | - | - | - | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | - | - | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | + | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | - | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
J | Staphylococcus aureus | - | - | - | - | - | - | - | + | + | + | + | + | + | + |
Staphylococcus aureus | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | + | + | + | + | + | + | + | |
Escherichia coli | - | - | - | - | - | - | - | - | - | + | + | + | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | - | - | - | - | - | + | + | |
Klebsiella Pneumoniae | - | - | - | - | - | - | - | + | + | + | + | + | + | + |
By table 1 and table 2 as can be seen, when the weight ratio of Cefuroxime Sodium and sodium-tazobactam is 15: 1, the effect that the MIC and the weight ratio of staphylococcus aureus, escherichia coli and Klebsiella Pneumoniae is at 1: 1,2: 1,3: 1,5: 1 o'clock is suitable, but the consumption of the sodium-tazobactam that price is very high reduces greatly, can significantly reduce the cost of this compound preparation.
Claims (1)
1, a kind of combination of Cefuroxime sodium and tazobactam for injection is made up of hot sodium of cephalo and sodium-tazobactam, and it is characterized in that: the weight ratio of described Cefuroxime Sodium and sodium-tazobactam is 15: 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510090387 CN1732949A (en) | 2005-08-16 | 2005-08-16 | Composition of cefuroxime sodium and tazobactam sodium for injection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510090387 CN1732949A (en) | 2005-08-16 | 2005-08-16 | Composition of cefuroxime sodium and tazobactam sodium for injection |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1732949A true CN1732949A (en) | 2006-02-15 |
Family
ID=36075705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510090387 Pending CN1732949A (en) | 2005-08-16 | 2005-08-16 | Composition of cefuroxime sodium and tazobactam sodium for injection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1732949A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101850105A (en) * | 2010-04-06 | 2010-10-06 | 邓学峰 | Cefuroxime sodium composite medicine |
-
2005
- 2005-08-16 CN CN 200510090387 patent/CN1732949A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101850105A (en) * | 2010-04-06 | 2010-10-06 | 邓学峰 | Cefuroxime sodium composite medicine |
CN101850105B (en) * | 2010-04-06 | 2012-06-27 | 邓学峰 | Cefuroxime sodium composite medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5410748B2 (en) | Pharmaceutical composition comprising an antibacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol | |
Pontikis et al. | Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria | |
Chernish et al. | Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis | |
Russo et al. | In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii | |
EP3609478B1 (en) | Nanosystems comprising silver and antibiotics and their use for the treatment of bacterial infections | |
Goa et al. | Panipenem/betamipron | |
Greer | Doripenem (Doribax): the newest addition to the carbapenems | |
EP1044006B1 (en) | Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection | |
CN1729987A (en) | Cefuroxime sodium and sulbactam sodium composition for injection | |
KR20140035376A (en) | Compositions comprising antibacterial agent and tazobactam | |
Lynch III et al. | Infections Due to Acinetobacter baumannii–calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options | |
CN1732949A (en) | Composition of cefuroxime sodium and tazobactam sodium for injection | |
CN1732950A (en) | Composition of cefuroxime sodium and tazobactam sodium for injection | |
CA2686348A1 (en) | Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems | |
CN1742735A (en) | Cefuroxime oral antibacnterial composition | |
Engel | Multidrug-resistant gram-negative bacteria: trends, risk factors, and treatments | |
Piyasirisilp et al. | Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj Hospital | |
WO2010064261A1 (en) | Synergistic combinations of aztreonam with the carbapenems meropenem and ertapenem | |
Saikia et al. | Antibiotics: From Mechanism of Action to Resistance and Beyond | |
CN114028418B (en) | Antibacterial composition containing chitosan oligosaccharide and application thereof | |
Yokota et al. | In vitro synergism of FR-31564, a new phosphonic acid antibiotic | |
Al-Dahmoshi et al. | Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections | |
Quintiliani et al. | Potential role of trimethoprim-sulfamethoxazole in the treatment of serious hospital-acquired bacterial infections | |
CN102125562B (en) | Medicinal composition for injection for treating superbug | |
BALIGA | MIC distribution profile of newer antibiotics among gram-negative bacteria in a tertiary care centre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |